TW202513092A - 用於治療補體介導之疾病及病症之方法 - Google Patents

用於治療補體介導之疾病及病症之方法 Download PDF

Info

Publication number
TW202513092A
TW202513092A TW113122096A TW113122096A TW202513092A TW 202513092 A TW202513092 A TW 202513092A TW 113122096 A TW113122096 A TW 113122096A TW 113122096 A TW113122096 A TW 113122096A TW 202513092 A TW202513092 A TW 202513092A
Authority
TW
Taiwan
Prior art keywords
seq
amino acid
acid sequence
antibody
region
Prior art date
Application number
TW113122096A
Other languages
English (en)
Chinese (zh)
Inventor
彼得 佛拉瑟
格雷厄姆 帕里
南希 斯塔利亞諾
聖帝普 帕尼克爾
Original Assignee
美商生物維瑞提夫美國公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商生物維瑞提夫美國公司 filed Critical 美商生物維瑞提夫美國公司
Publication of TW202513092A publication Critical patent/TW202513092A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW113122096A 2017-03-14 2018-03-14 用於治療補體介導之疾病及病症之方法 TW202513092A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762471190P 2017-03-14 2017-03-14
US62/471,190 2017-03-14
US201762553059P 2017-08-31 2017-08-31
US62/553,059 2017-08-31

Publications (1)

Publication Number Publication Date
TW202513092A true TW202513092A (zh) 2025-04-01

Family

ID=61873979

Family Applications (2)

Application Number Title Priority Date Filing Date
TW113122096A TW202513092A (zh) 2017-03-14 2018-03-14 用於治療補體介導之疾病及病症之方法
TW107108658A TWI848905B (zh) 2017-03-14 2018-03-14 用於治療補體介導之疾病及病症之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW107108658A TWI848905B (zh) 2017-03-14 2018-03-14 用於治療補體介導之疾病及病症之方法

Country Status (14)

Country Link
US (1) US20210115116A1 (https=)
EP (1) EP3596121A1 (https=)
JP (3) JP7293122B2 (https=)
KR (2) KR20260039796A (https=)
CN (1) CN110753701A (https=)
AU (2) AU2018236267B2 (https=)
BR (1) BR112019018950A2 (https=)
CA (1) CA3055781A1 (https=)
CR (1) CR20190468A (https=)
IL (2) IL325084A (https=)
MX (2) MX2019010994A (https=)
SG (1) SG11201907583TA (https=)
TW (2) TW202513092A (https=)
WO (1) WO2018170145A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
CA2981321A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
CN110300520B (zh) 2016-10-12 2022-10-04 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
CN113260375B (zh) 2018-12-13 2024-10-01 阿尔金克斯有限公司 针对人补体因子C2b的抗体及使用方法
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
MX2022006334A (es) * 2019-11-26 2022-06-22 Omeros Corp Metodos para tratar y/o prevenir el sindrome de neumonia idiopatica (ips) y/o el sindrome de fuga capilar (cls) y/o el sindrome de injerto (es) y/o la sobrecarga de fluidos (fo) asociados con el trasplante de celulas madre hematopoyeticas.
FI129383B (en) * 2020-06-15 2022-01-31 Faron Pharmaceuticals Oy Stable anti-clever-1 antibody formulation
IL300376A (en) * 2020-08-06 2023-04-01 Bioverativ Usa Inc Inflammatory cytokines and fatigue in subjects with complement-mediated disease
WO2022212645A1 (en) 2021-03-31 2022-10-06 Bioverativ Usa Inc. Reducing surgery-associated hemolysis in cold agglutinin disease patients
CN117769434A (zh) 2021-05-20 2024-03-26 黛安瑟斯医疗运营公司 与C1s结合的抗体和其用途
CN120757653A (zh) 2021-07-13 2025-10-10 迈威(美国)生物治疗有限公司 抗c1s抗体和其用途
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
CA3260415A1 (en) * 2022-06-24 2023-12-28 Bioverativ Usa Inc. METHODS OF TREATMENT FOR COMPLEMENT-MEDICATED DISEASES
WO2024112734A1 (en) 2022-11-21 2024-05-30 Dianthus Therapeutics Opco, Inc. Antibodies that bind to c1s and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
WO2015084999A1 (en) * 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays

Also Published As

Publication number Publication date
AU2025204392A1 (en) 2025-07-03
BR112019018950A2 (pt) 2020-04-22
KR20260039796A (ko) 2026-03-20
WO2018170145A1 (en) 2018-09-20
JP2020511469A (ja) 2020-04-16
MX2019010994A (es) 2020-12-01
US20210115116A1 (en) 2021-04-22
CR20190468A (es) 2019-12-17
SG11201907583TA (en) 2019-09-27
CA3055781A1 (en) 2018-09-20
IL269174B1 (en) 2026-01-01
KR102934707B1 (ko) 2026-03-06
TWI848905B (zh) 2024-07-21
CN110753701A (zh) 2020-02-04
JP2025072437A (ja) 2025-05-09
JP7293122B2 (ja) 2023-06-19
MX2025010483A (es) 2025-10-01
IL269174A (en) 2019-11-28
JP2023071824A (ja) 2023-05-23
IL325084A (en) 2026-02-01
AU2018236267B2 (en) 2025-03-13
TW201842931A (zh) 2018-12-16
EP3596121A1 (en) 2020-01-22
AU2018236267A1 (en) 2019-09-26
KR20190128676A (ko) 2019-11-18

Similar Documents

Publication Publication Date Title
TWI848905B (zh) 用於治療補體介導之疾病及病症之方法
JP2023026536A (ja) 補体のインヒビターによる発作性夜間血色素尿症患者の処置
KR102553777B1 (ko) 다양한 질환 및 장애의 치료를 위해 masp-3을 억제하는 조성물 및 방법
AU2022215307B2 (en) Methods of treating autoimmune and alloimmune disorders
AU2013337638B2 (en) Anti-complement C1s antibodies and uses thereof
ES2926700T3 (es) Anticuerpos anti Eotaxina-2 que reconocen quimiocinas de unión a CCR3 adicionales
JP2020524696A (ja) Ｃ５ａ活性のインヒビターでの炎症性疾患の処置
US20250145696A1 (en) Methods for treating complement-mediated diseases and disorders
HK40022920A (en) Methods for treating complement-mediated diseases and disorders
WO2025094976A1 (ja) ヘモジデリンの沈着及び／又は滑膜肥厚の改善又は抑制剤
NZ791361A (en) Engineered anti-il-2 antibodies
BR112018069283B1 (pt) Anticorpos monoclonais contra o sítio ativo de fator xi e usos dos mesmos
NZ728179A (en) Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders
NZ728179B2 (en) Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the treatment of various diseases and disorders